Outcome according to the primary extranodal site of localization
| Extranodal site . | 5-y survival rates, % . | ||
|---|---|---|---|
| OS (95% CI, %) . | CSS (95% CI, %) . | PFS (95% CI, %) . | |
| Skin | 100 | 100 | 53 (22-77) |
| Orbit | 80 (40-95) | 87 (39-98) | 23 (1-62) |
| Conjunctiva | 100 | 100 | 100 |
| Salivary gland | 97 (81-100) | 97 (81-100) | 67 (48-81) |
| Upper airways | 46 (7-80) | 67 (5-95) | 0 |
| Lung | 100 | 100 | 75 (41-91) |
| Breast | 100 | 100 | 33 (1-77) |
| Thyroid | 100 | 100 | 100 |
| Urinary tract | 100 | 0 | 0 |
| Liver | 0 | 0 | 0 |
| Bowel | 100 | 100 | 63 (24-87) |
| Multiple sites, all5-150 | 77 (43-93) | 86 (51-97) | 25 (3-58) |
| Multiple MALT organs, only | 100 | 100 | 0 |
| Extranodal site . | 5-y survival rates, % . | ||
|---|---|---|---|
| OS (95% CI, %) . | CSS (95% CI, %) . | PFS (95% CI, %) . | |
| Skin | 100 | 100 | 53 (22-77) |
| Orbit | 80 (40-95) | 87 (39-98) | 23 (1-62) |
| Conjunctiva | 100 | 100 | 100 |
| Salivary gland | 97 (81-100) | 97 (81-100) | 67 (48-81) |
| Upper airways | 46 (7-80) | 67 (5-95) | 0 |
| Lung | 100 | 100 | 75 (41-91) |
| Breast | 100 | 100 | 33 (1-77) |
| Thyroid | 100 | 100 | 100 |
| Urinary tract | 100 | 0 | 0 |
| Liver | 0 | 0 | 0 |
| Bowel | 100 | 100 | 63 (24-87) |
| Multiple sites, all5-150 | 77 (43-93) | 86 (51-97) | 25 (3-58) |
| Multiple MALT organs, only | 100 | 100 | 0 |
Patients with multiple MALT sites with or without nodal or bone marrow (or both) involvement.